Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

Neogenomics stock target cut, maintains buy rating

EditorAhmed Abdulazez Abdulkadir
Published 02/05/2024, 08:46 pm

On Thursday, BTIG adjusted its price target for Neogenomics (NASDAQ: NEO), reducing it to $21 from the previous $23, while retaining a Buy rating on the stock. The revision came after the company's first-quarter results, which saw Neogenomics outperforming revenue expectations with a 4% beat and maintaining another quarter of positive adjusted EBITDA, along with reiterating its 2024 guidance.

The price target adjustment was attributed to market reactions following the company's quarterly earnings call, where a 9% drop in Neogenomics' shares was observed. The decline was linked to management's discussion about evaluating mergers and acquisitions (M&A), which was initially thought to potentially involve dilutive financing. However, management later clarified that their M&A strategy might focus on smaller scale deals rather than large transactions, aiming for deals that would quickly contribute to the company's adjusted EBITDA.

Neogenomics has outlined its priorities in the minimal residual disease (MRD) space, which include winning its RaDaR lawsuit against Natera (NASDAQ:NTRA), developing a next-generation RaDaR test to avoid intellectual property issues, or pursuing M&A through acquisitions, licensing agreements, or technology transfers. The company's management underscored their intention for any deal to be accretive to adjusted EBITDA as soon as possible.

The biotechnology firm also appears to have overcome regulatory concerns, with the market not fully appreciating the resolution of uncertainties regarding the Food and Drug Administration's (FDA) final rule on laboratory developed tests (LDTs), which turned out to be more lenient than expected. BTIG believes that Neogenomics is well-positioned to drive profitable growth, leading to the reaffirmation of the Buy rating despite the lowered price target.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.